California Court Allows Antitrust Counterclaim, Intensifying Biotech Legal Dispute

In a recent legal development, a California federal court has decided not to dismiss an antitrust counterclaim brought by Zymo Research Corp. against its competitor Qiagen GmbH. Zymo Research accused Qiagen of engaging in anti-competitive practices by filing a “sham” patent infringement lawsuit, allegedly with the intent to stifle competition in the DNA extraction market. The court’s decision marks a significant moment in the ongoing legal battle between these two entities within the biotech industry. This case highlights the judiciary’s role in scrutinizing potentially frivolous lawsuits that might be used strategically to weaken market competition. For further details on the proceedings, visit the Law360 article.